The study of severe cutaneous drug hypersensitivity reactions from a systems biology perspective

Current Opinion in Allergy and Clinical Immunology

Volumn 14, Issue 4, 2014, Pages 301-306

  Perkins, James R ^a   Ayuso, Pedro ^a   Cornejo García, José A ^a,b   Ranea, Juan A ^a,c  

^a UNIVERSITY OF MÁLAGA   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

human leukocyte antigen; hypersensitivity drug reactions; Stevens Johnson syndrome; systems biology; T cells; toxic epidermal necrolysis

Indexed keywords

CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CXCR4; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; GRANULYSIN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 5; INTERLEUKIN 6; PERFORIN; T LYMPHOCYTE RECEPTOR; HLA ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR;

ACUTE PHASE RESPONSE; ALTERNATIVE RNA SPLICING; CYTOTOXIC T LYMPHOCYTE; DISEASE SEVERITY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEREDITY; HIGH THROUGHPUT SCREENING; HLA SYSTEM; HUMAN; META ANALYSIS (TOPIC); NATURAL KILLER CELL; POLYPHARMACOLOGY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; QUANTITATIVE TRAIT LOCUS; REVIEW; STEVENS JOHNSON SYNDROME; SYSTEMS BIOLOGY; T LYMPHOCYTE ACTIVATION; TOXIC EPIDERMAL NECROLYSIS; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; META ANALYSIS;

DRUG HYPERSENSITIVITY; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HLA ANTIGENS; HUMANS; RECEPTORS, ANTIGEN, T-CELL; STEVENS-JOHNSON SYNDROME; SYSTEMS BIOLOGY;

EID: 84903775014     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000076     Document Type: Review

References (79)

1. Chung W-H, Hung S-I. Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis. J Dermatol Sci 2012; 66:190-196.
2. Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol 1994; 102:28S-30S.
3. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331:1272-1285.
4. Mockenhaupt M. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol 2011; 7:803-813.
5. Lee H-Y, Chung W-H. Toxic epidermal necrolysis: the year in review. Curr Opin Allergy Clin Immunol 2013; 13:330-336.
6. Mockenhaupt M. Severe cutaneous adverse reactions. In: Burgdorf W, Plewig G, Wolff HH, Landthaler M, editors. Braun-Falco's Dermatology, 3rd ed. Springer; 2008.
7. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333:1600-1607.
8. Nassif A, Bensussan A, Boumsell L, et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004; 114:1209-1215.
9. Ko T-M, Chung W-H, Wei C-Y, et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol 2011; 128:1266-1276; e11.
10. Chung W-H, Hung S-I, Yang J-Y, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008; 14:1343-1350.
11. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282:490-493.
12. Chang HY, Cooper ZA, Swetter SM, Marinkovich MP. Kinetics and specificity of Fas ligand induction in toxic epidermal necrolysis. Arch Dermatol 2004; 140:242-244.
13. Abe R, Shimizu T, Shibaki A, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol 2003; 162:1515-1520.
14. Nassif A, Bensussan A, Dorothée G, et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol 2002; 118:728-733.
15. Posadas SJ, Padial A, Torres MJ, et al. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol 2002; 109:155-161.
16. Abe R, Yoshioka N, Murata J, et al. Granulysin as a marker for early diagnosis of the Stevens-Johnson syndrome. Ann Intern Med 2009; 151:514-515.
17. Bellón T, Alvarez L, Mayorga C, et al. Differential gene expression in drug hypersensitivity reactions: induction of alarmins in severe bullous diseases. Br J Dermatol 2010; 162:1014-1022.
18. Bellón T, Blanca M. The innate immune system in delayed cutaneous allergic reactions to medications. Curr Opin Allergy Clin Immunol 2011; 11:292-298.
19. Correia O, Delgado L, Barbosa IL, et al. Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis. J Am Acad Dermatol 2002; 47:58-62.
20. Nassif A, Moslehi H, Le Gouvello S, et al. Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol 2004; 123:850-855.
21. Caproni M, Torchia D, Schincaglia E, et al. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis. Br J Dermatol 2006; 155:722-728.
22. Tapia B, Padial A, Sánchez-Sabaté E, et al. Involvement of CCL27-CCR10 interactions in drug-induced cutaneous reactions. J Allergy Clin Immunol 2004; 114:335-340.
23. Roujeau JC, Huynh TN, Bracq C, et al. Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol 1987; 123:1171-1173.
24. Chung W-H, Hung S-I, Hong H-S, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428:486.
25. Hung S-I, Chung W-H, Jee S-H, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006; 16:297-306.
26. Tangamornsuksan W, Chaiyakunapruk N, Somkrua R, et al. Relationship between the HLA-B1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol 2013; 149:1025-1032.
27. Ueta M, Tokunaga K, Sotozono C, et al. HLA class I and II gene polymorphisms in Stevens-Johnson syndrome with ocular complications in Japanese. Mol Vis 2008; 14:550-555.
28. Lonjou C, Thomas L, Borot N, et al. A marker for Stevens-Johnson syndrome : ethnicity matters. Pharmacogenomics J 2006; 6:265-268.
29. Hung S-I, Chung W-H, Liou L-B, et al. HLA-B5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005; 102:4134-4139.
30. Tassaneeyakul W, Jantararoungtong T, Chen P, et al. Strong association between HLA-B5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genom 2009; 19:704-709.
31. Kang H-R, Jee YK, Kim Y-S, et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genom 2011; 21:303-307.
32. Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in Stevens- Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genom 2008; 18:99-107.
33. Tohkin M, Kaniwa N, Saito Y, et al. A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Pharmacogenom J 2013; 13:60-69.
34. Colombo S, Rauch A, Rotger M, et al. The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. J Infect Dis 2008; 198:864-867.
35. Maekawa K, Nishikawa J, Kaniwa N, et al. Development of a rapid and inexpensive assay for detecting a surrogate genetic polymorphism of HLAB 58:01: a partially predictive but useful biomarker for allopurinol-related Stevens-Johnson syndrome/toxic epidermal necrolysis in Japanese. Drug Metab Pharmacokinet 2012; 27:447-450.
36. Lavergne SN, Park BK, Naisbitt DJ. The roles of drug metabolism in the pathogenesis of T-cell-mediated drug hypersensitivity. Curr Opin Allergy Clin Immunol 2008; 8:299-307.
37. Pichler WJ, Beeler A, Keller M, et al. Pharmacological interaction of drugs with immune receptors: the p-i concept. Allergol Int 2006; 55:17-25.
38. Pirmohamed M, Naisbitt DJ, Gordon F, Park BK.Thedangerhypothesis: potential role in idiosyncratic drug reactions. Toxicology 2002; 181-182:55-63.
39. Chessman D, Kostenko L, Lethborg T, et al. Human leukocyte antigen class Irestricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 2008; 28:822-832.
40. Illing PT, Vivian JP, Dudek NL, et al. Immune self-reactivity triggered by drugmodified HLA-peptide repertoire. Nature 2012; 486:554-558.
41. Ostrov DA, Grant BJ, Pompeu YA, et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci U S A 2012; 109:9959-9964.
42. Zucman D, Truchis P, de Majerholc C, et al. Prospective screening for human leukocyte antigen-B5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J Acquir Immune Defic Syndr 2007; 45:1-3.
43. Nolan D. HLA-B5701 screening prior to abacavir prescription: clinical and laboratory aspects. Crit Rev Clin Lab Sci 2009; 46:153-165.
44. Nieves Calatrava D, Calle-Martín O, de la Iribarren-Loyarte JA, et al. Costeffectiveness analysis of HLA-B5701 typing in the prevention of hypersensitivity to abacavir in HIV+ patients in Spain. Enfermedades Infecc Microbiol Clin 2010; 28:590-595.
45. Mallal S, Phillips E, Carosi G, et al. HLA-B5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358:568-579.
46. Génin E, Schumacher M, Roujeau J-C, et al. Genome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Europe. Orphanet J Rare Dis 2011; 6:52.
47. McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A3101 and carbamazepine- induced hypersensitivity reactions in Europeans. N Engl J Med 2011; 364:1134-1143.
48. Shen Y, Nicoletti P, Floratos A, et al. Genome-wide association study of serious blistering skin rash caused by drugs. Pharmacogenomics J 2012; 12:96-104.
49. Ozeki T, Mushiroda T, Yowang A, et al. Genome-wide association study identifies HLA-A3101 allele as a genetic risk factor for carbamazepineinduced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 2011; 20:1034-1041.
50. Ueta M, Sotozono C, Nakano M, et al. Association between prostaglandin E receptor 3 polymorphisms and Stevens-Johnson syndrome identified by means of a genome-wide association study. J Allergy Clin Immunol 2010; 126:1218.e10-1225. e10.
51. Shin S, Park JS, Kim Y-J, et al. Differential gene expression profile in PBMCs from subjects with AERD and ATA: a gene marker for AERD. Mol Genet Genomics 2012; 287:361-371.
52. Cheong HS, Park S-M, Kim M-O, et al. Genome-wide methylation profile of nasal polyps: relation to aspirin hypersensitivity in asthmatics. Allergy 2011; 66:637-644.
53. Sekigawa T, Tajima A, Hasegawa T, et al. Gene-expression profiles in human nasal polyp tissues and identification of genetic susceptibility in aspirinintolerant asthma. Clin Exp Allergy 2009; 39:972-981.
54. Arazi A, Pendergraft WF 3rd, Ribeiro RM, et al. Human systems immunology: hypothesis-based modeling and unbiased data-driven approaches. Semin Immunol 2013; 25:193-200.
55. Somkrua R, Eickman EE, Saokaew S, et al. Association of HLA-B5801 allele and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. BMC Med Genet 2011; 12:118.
56. Szklarczyk D, Franceschini A, Kuhn M, et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res 2011; 39:D561-568.
57. Ranea J,Morilla I,Lees J, et al. FFinding the 'DarkMatter' in human and yeast protein network prediction and modelling. PLoS Comput Biol 2010; 6:e1000945.
58. Renkonen J, Mattila P, Parviainen V, et al. A network analysis of the single nucleotide polymorphisms in acute allergic diseases. Allergy 2010; 65:40-47.
59. Renkonen J, Joenväärä S, Parviainen V, et al. Network analysis of single nucleotide polymorphisms in asthma. J Asthma Allergy 2010; 3:177-186.
60. Welter D, MacArthur J, Morales J, et al. The NHGRIGWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res 2014; 42:D1001-D1006.
61. Edwards SL, Beesley J, French JD, Dunning AM. Beyond GWASs: illuminating the dark road from association to function. Am J Hum Genet 2013; 93:779-797.
62. Dunham I, Kundaje A, Aldred SF, et al. An integrated encyclopedia of DNA elements in the human genome. Nature 2012; 489:57-74.
63. Kulkarni S, Savan R, Qi Y, et al. Differential microRNA regulation of HLA-C expression and its association with HIV control. Nature 2011; 472:495-498.
64. Thomas R, Apps R, Qi Y, et al. HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat Genet 2009; 41:1290-1294.
65. Dimas AS, Deutsch S, Stranger BE, et al. Common regulatory variation impacts gene expression in a cell type-dependent manner. Science 2009; 325:1246-1250.
66. Couto Alves A, Bruhn S, Ramasamy A, et al. Dysregulation of complement system and CD4+ T cell activation pathways implicated in allergic response. PLoS One 2013; 8:e74821.
67. Perkins JR, Antunes-Martins A, Calvo M, et al. A comparison of RNA-seq and exon arrays for whole genome transcription profiling of the L5 spinal nerve transection model of neuropathic pain in the rat. Mol Pain 2014; 10:7.
68. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 2009; 10:57-63.
69. Furey TS, Sethupathy P. Genetics driving epigenetics. Science 2013; 342:705-706.
70. Clemente MJ, Przychodzen B, Jerez A, et al. Deep sequencing of the T-cell receptor repertoire in CD8+ T-large granular lymphocyte leukemia identifies signature landscapes. Blood 2013; 122:4077-4085.
71. Wu D, Sherwood A, Fromm JR, et al. High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia. Sci Transl Med 2012; 4:134ra63.
72. Robins HS, Campregher PV, Srivastava SK, et al. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood 2009; 114:4099-4107.
73. Freeman JD, Warren RL, Webb JR, et al. Profiling the T-cell receptor betachain repertoire by massively parallel sequencing. Genome Res 2009; 19:1817-1824.
74. Moya-García AA, Ranea JAG. Insights into polypharmacology from drugdomain associations. Bioinforma Oxf Engl 2013; 29:1934-1937.
75. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008; 4:682-690.
76. Mestres J, Gregori-Puigjané E, Valverde S, Solé RV. The topology of drug-target interaction networks: implicit dependence on drug properties and target families. Mol Biosyst 2009; 5:1051-1057.
77. Law V, Knox C, Djoumbou Y, et al. DrugBank 4. 0: shedding new light on drug metabolism. Nucleic Acids Res 2014; 42:D1091-D1097.
78. Gaulton A, Bellis LJ, Bento AP, et al. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res 2012; 40:D1100-D1107.
79. Kuhn M, Szklarczyk D, Pletscher-Frankild S, et al. STITCH 4 integration of protein-chemical interactions with user data. Nucleic Acids Res 2014; 42:D401-D407.